ES2128309T3 - Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa. - Google Patents

Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa.

Info

Publication number
ES2128309T3
ES2128309T3 ES91306903T ES91306903T ES2128309T3 ES 2128309 T3 ES2128309 T3 ES 2128309T3 ES 91306903 T ES91306903 T ES 91306903T ES 91306903 T ES91306903 T ES 91306903T ES 2128309 T3 ES2128309 T3 ES 2128309T3
Authority
ES
Spain
Prior art keywords
acid
aminoethanesulphonic
ethanesulphonic
propanesulphonic
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91306903T
Other languages
English (en)
Inventor
Frederick Jacob Bloomfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bloomfield DA
Original Assignee
Bloomfield DA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bloomfield DA filed Critical Bloomfield DA
Application granted granted Critical
Publication of ES2128309T3 publication Critical patent/ES2128309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPUESTOS DE ION HIBRIDO SELECCIONADOS DE: TAURINA (ACIDO 2-AMINOETANOSULFONICO), 2(N-MORFOLINO) ACIDO ETANOSULFONICO (MES), N-(2 ACETAMINO) ACIDO IMINODIACETICO (ADA), PIPERACINA-N, N'' BIS (ACIDO 2-ETANOSULFONICO (PIPES), ACIDO N-(2-ACETAMIDO)-2-AMINOETANOSULFONICO (ACES), ACIDO N, N-BIS (2-HIDROXIETILO)-2-AMINOETANOSULFONICO (BES), 3-(N-MORFOLINO) PROPANOSULFONICO (MOPS), ACIDO N-N[TRIS (HIDROXIMETILO)-METILO]-2-AMINOETANOSULFONICO (TES), ACIDO N-2-HIDROXIETILPIPERAZINA-N''-2-ETANOSULFONICO (HEPES), ACIDO N-2-HIDROXIETILPIPERAZINA-N''3-PROPANOSULFONICO (H)EPPS), ACIDO 2-(CICLOEXILAMINO) ETANOSULFONICO (CHES) O ACIDO 3-(CICLOEXILAMINO) PROPANOSULFONICO (CAPS), Y SUS DERIVADOS N-HALO PUEDEN USARSE SEPARADAMENTE O EN COMBINACION EN EL TRATAMIENTO DE CONDICIONES CLINICAS RELACIONADAS MEDIANTE LA ESTIMULACION DE ACTIVIDAD MIELOPEROXIDASA, QUE A SU VEZ ESTIMULA LA PRODUCCION DE ACIDO HIPOCLOROSO "IN VIVO", QUE LLEVA "INTER ALIA" A LA INACTIVACION REALZADA LEUKOTRIENA.
ES91306903T 1990-07-30 1991-07-29 Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa. Expired - Lifetime ES2128309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE274190 1990-07-30

Publications (1)

Publication Number Publication Date
ES2128309T3 true ES2128309T3 (es) 1999-05-16

Family

ID=11036287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91306903T Expired - Lifetime ES2128309T3 (es) 1990-07-30 1991-07-29 Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa.

Country Status (8)

Country Link
US (1) US5248680A (es)
EP (1) EP0469813B1 (es)
JP (1) JPH0597666A (es)
AT (1) ATE175112T1 (es)
AU (1) AU641529B2 (es)
CA (1) CA2048068A1 (es)
DE (1) DE69130692T2 (es)
ES (1) ES2128309T3 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
JPH10513452A (ja) * 1995-02-03 1998-12-22 コスメダーム・テクノロジーズ 皮膚刺激を軽減するための製剤及び方法
US5716959A (en) * 1996-02-13 1998-02-10 T. Ronald Theodore Method of treating disease with piperazine zwitterion compounds
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
CA2311796A1 (en) 1997-11-28 1999-06-10 Peter M. Pugliese Zwitterionic fatty acid compounds for anti-inflammation
US6448251B1 (en) * 1997-11-28 2002-09-10 Peter T. Pugliese Zwitterionic-fatty acid compounds having anti-inflammatory properties
RU2156129C1 (ru) * 2000-03-14 2000-09-20 Закрытое акционерное общество "Корпорация ОЛИФЕН" Биологически активное средство тонизирующего действия
CA2386985A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
US20040116521A1 (en) * 2000-09-14 2004-06-17 Waldemar Gottardi Fungicidal agent containing n-chlorotaurine and use thereof
FR2816837A1 (fr) * 2000-11-17 2002-05-24 Oreal Utilisation d'au moins un derive amino sulfonique dans une composition destinee a favoriser la desquamation de la peau
GB0109428D0 (en) * 2001-04-17 2001-06-06 Process & Ind Design Consultan Therapeutic compositions
DE10133197A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
US20060127342A1 (en) * 2004-12-09 2006-06-15 Georgia Levis Taurine-based compositions, therapeutic methods, and assays
EP2120555A1 (en) * 2007-01-31 2009-11-25 Adam Heller Methods and compositions for the treatment of pain
MX2012003212A (es) 2009-09-17 2012-09-07 North Texas Medical Ass Papel del acido n-2-hidroxi-etil-piperazina-n´-2-etano sulfonico (hepes) en el control del dolor y reversion de lesiones por desmielinizacion.
US20140377814A1 (en) * 2012-02-07 2014-12-25 Industry-Academic Cooperation Foundation, Yonsei University Method For The Fixation Or Conversion Of High-Pressure Carbon Dioxide Using Barophilic Sulfur-Oxidizing Chemolithoautotrophs
JP2014040393A (ja) * 2012-08-23 2014-03-06 Taisho Pharmaceutical Co Ltd 遺伝子発現調節剤
TW201619605A (zh) * 2014-10-24 2016-06-01 Shiseido Co Ltd 用以改善起因於角質層剝離之抑制或促進之肌膚狀態的美容方法及評價方法
RU2614691C2 (ru) * 2015-07-14 2017-03-28 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Гепатопротекторное средство

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52977B1 (en) * 1981-11-24 1988-04-27 Pascale Ltd Protective composition for users of cyanoacrylate adhesives
JPS592686A (ja) * 1982-06-25 1984-01-09 Green Cross Corp:The ミエロペルオキシダ−ゼの粉末製剤
EP0100827B1 (en) * 1982-08-17 1986-09-03 Rosical Limited Pharmaceutical composition containing an aliphatic aminosulphonic acid
IE853206L (en) * 1985-12-18 1987-06-18 Sullivan Donncha O Use of aminosulfonic acids in treatment of inflammatory¹conditions
GB8713091D0 (en) * 1987-06-04 1987-07-08 Millrine W P Pharmaceutical compositions
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics

Also Published As

Publication number Publication date
EP0469813A3 (en) 1992-11-19
AU641529B2 (en) 1993-09-23
US5248680A (en) 1993-09-28
EP0469813A2 (en) 1992-02-05
JPH0597666A (ja) 1993-04-20
DE69130692T2 (de) 1999-09-09
EP0469813B1 (en) 1998-12-30
CA2048068A1 (en) 1992-01-31
DE69130692D1 (de) 1999-02-11
AU8133291A (en) 1992-02-13
ATE175112T1 (de) 1999-01-15

Similar Documents

Publication Publication Date Title
ES2128309T3 (es) Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
ATE333275T1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
DE69123960D1 (de) Behandlung von entzündungen
FR2670491B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE69606840D1 (de) Monohydrate von Aminobenzensulfonsäurederivaten und Verfahren zu ihrer Herstellung
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE157007T1 (de) 6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon
DK324185A (da) 2-substituerede 1,3-propylidendiphosphonatderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf
BR9609565A (pt) Composição fungicida e método para controle de doenças das plantas causadas por fungos patogênicos das plantas
ATE132494T1 (de) Substituierte 3-piperazinylalkyl 2,3-dihydro-4h- 1,3-benzoxazin-4-one, deren herstellung und verwendung in heilkunde
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE73785T1 (de) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amin - 6h-1,3,4-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
NO971743D0 (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
NO179472C (no) Opplösning omfattende benzoxoniumklorid for behandling av kontaktlinser, og anvendelse derav til konservering av kontaktlinser og legemidler for öynene
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
ITMI920979A1 (it) N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
DE69400352D1 (de) 3- oder 4-Glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches Mittel
IT1223395B (it) Composti ad attivita' cardiovascolare
ATE147396T1 (de) N-substituierte aminomethandiphosphonsäuren
FR2588190B1 (fr) Procede de desinfection de milieux interstitiels charges en germes pathogenes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 469813

Country of ref document: ES